Preview
Carbamazepine is a drug with rapidly expanding indications. However, it has been linked with blood cell abnormalities, including aplastic anemia, leukopenia, neutropenia, and thrombocytopenia. Should physicians be concerned about its hematologic risks? When must therapy be discontinued? Dr Bertolino describes a case of carbamazepine-induced leukopenia and neutropenia and discusses the importance of patient monitoring during therapy.